1. Home
  2. LAES vs IFRX Comparison

LAES vs IFRX Comparison

Compare LAES & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SEALSQ Corp

LAES

SEALSQ Corp

BUY

Current Price

$1.58

Market Cap

368.9M

Sector

Technology

ML Signal

BUY

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.57

Market Cap

225.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAES
IFRX
Founded
2022
2007
Country
Switzerland
Germany
Employees
N/A
65
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
368.9M
225.5M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
LAES
IFRX
Price
$1.58
$1.57
Analyst Decision
Buy
Strong Buy
Analyst Count
2
9
Target Price
$5.88
★ $7.68
AVG Volume (30 Days)
★ 3.6M
670.2K
Earning Date
09-11-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$59.43
N/A
Revenue Next Year
$41.92
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.52
$0.80
52 Week High
$7.64
$2.95

Technical Indicators

Market Signals
Indicator
LAES
IFRX
Relative Strength Index (RSI) 20.60 42.57
Support Level N/A $0.81
Resistance Level $2.56 $2.94
Average True Range (ATR) 0.12 0.12
MACD -0.05 0.02
Stochastic Oscillator 5.61 56.57

Price Performance

Historical Comparison
LAES
IFRX

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: